Quadt, Cornelia
Novartis (Switzerland)
3 papers on CoChat
Most cited papers
- Verified
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature
PI3K/AKT/mTOR signaling in cancerCancer Genomics and Diagnostics
Cited by 588
- Verified
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine
PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies
Cited by 332
- Verified
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
Schlereth, B., Quadt, C., Dreier, T., Kufer, P., Lorenczewski, G., Prang, N., Brandl, C., Lippold, S., Cobb, K., Brasky, K., et al. (2006) · Cancer Immunology, Immunotherapy
Monoclonal and Polyclonal Antibodies ResearchT-cell and B-cell Immunology
Cited by 103
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free